38 Week Extension Study to CAIN457C2303

Summary

A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

Timeline

Start

2010-03

Primary completion

2011-01

Completion

2011-01

Outcome

Outcome not reported

Stopped: “Core Study in Behcet's disease with mostly active uveitis did not meet its primary endpoint”

Drugs

Indications